Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Concentric receives new order for electric water pumps from global OEM

Concentric AB has been awarded a contract to supply electrically driven and controlled coolant pumps to a global OEM of trucks and buses. The pump will be used for thermal management of the batteries and power electronics on their new range of mid-size electric trucks. This new pump utilises a larger motor than Concentric’s other e -pumps and with a nominal power output of 600W it can deliver a higher flowrate and pressure. Production will start in 2021 and the contract runs until 2025 with total sales estimated to amount to SEK 150 million. In order to strengthen the customer

Interim report June - September 2019

Quant releases the interim report for June - September 2019.June-September · Net sales for the period increased by 4.8% to EUR 47.9 (45.7) million due to the acquisition of Sataservice in August 2018. Organically, net sales decreased by 1.4% · During the quarter three contracts were won, one contract was renewed, three contracts were lost, and two contracts were divested, which on balance affected the contract portfolio negatively. Portfolio run rate annualized net sales at the end of the quarter was EUR 178.4 million, compared to EUR 186.6 million during the second quarter of 2019

Increase of number of shares and votes in Vicore Pharma

Gothenburg, November 29, 2019 – Vicore Pharma Holding AB (publ)’s (“Vicore Pharma”, or the “Company”) registered share capital and number of outstanding shares and votes have increased during the month of November 2019.As previously announced, the Company’s board of directors resolved on November 13, 2019, by virtue of the authorization by the annual general meeting held on May 15, 2019, on a directed share issue of 7,800,000 new shares at a subscription price of SEK 16 per share. Through the share issue, Vicore Pharma received issue proceeds of approximately SEK 125 million before issue

Q3 Interim financial report

Highlights Group revenue of SEK 229m during the quarter comprising growth of 17.2% (+0.1% proforma 2018 inclSørlie), despite a more challenging Swedish macroeconomic environment. EBITDA of SEK 26.5m (SEK 32.2m). Unrealized foreign exchange loss YTD in 2019 of SEK 9.9m (SEK 1.4m gain in 2018). New strategy to gain synergies in the market. Cost reduction program for 2020 initiated. Order backlog of SEK 97.1m per Q3 2019 (SEK 97.6m Q3 2018).

New number of shares in Handelsbanken

Due to an exchange of convertible notes in Svenska Handelsbanken AB, the number of Class A shares has increased by 2 199 669 shares and the number of votes has increased by 2 199 669.Following the increase, the total number of shares in Handelsbanken is 1 979 446 615 of which 1 944 195 286 are Class A shares and 35 251 329 are Class B shares. The total number of votes in Handelsbanken is 1 947 720 418,9.The share capital amounts to SEK 3 068 142 253,25 after the increase.   For further information, please contact:Lars Höglund, Head of Investor Relations: +46 8–701 51 70,+46 70–

LightLab Sweden and SAES Getters sign letter of intent for possible cooperation in the area of UV chips

LightLab Sweden has signed a letter of intent with SAES Getters S.p.A. (SAES). This letter of intent follows on the earlier time-limited cooperation agreement, under which the parties until 31 August 2019 have evaluated the future potential of LightLab's products for UV disinfection and the possibilities for a long-term closer cooperation between the companies. According to the signed letter of intent, the parties will now until 31 July 2020 continue discussions on possible collaborations within development, production, sales and marketing of UV chips for disinfection of water, air,

Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has received final approval from the Danish Medicines Agency for start of a clinical Phase II trial with the drug candidate SCO-101 in combination with chemotherapy in patients with drug resistant metastatic colorectal cancer. The study is conducted in two parts. The first interim results from this first part   are expected in Q2 2020 and the final study is expected to be available by the end of 2020.Clinical Phase II trial with SCO-101 in patients with drug resistant metastatic colorectal cancer Scandion

Interim report January-September 2019

Northmill Group AB (publ) publishes Interim report for the period January-September 2019Q3 2019 (Compared to the Q3 2018) · The loan portfolio increased by 26.7% to SEK 1 285 million (1 015) · Net interest income increased by 2.9% to SEK 76.0 million (73.9) · Operating income increased by 1.7% to SEK 84.4 million (83.0) · Profit before tax (EBT) decreased by 4.3% to SEK 26.9 million (28.1) January - September 2019 (Compared to the January - September 2018) · The loan portfolio increased by 26.7% to SEK 1 285 million (1 015) · Net interest income increased by 3.0% to

MPC Container Ships ASA reports Q3 and nine-month 2019 results

· Q3 2019 operating revenue USD 46.0 million. Q3 YTD 2019 operating revenue USD 140.5 million. · Q3 2019 EBITDA USD 4.5 million. Q3 YTD 2019 EBITDA USD 17.3 million. · Q3 2019 net loss USD 11.4 million. Q3 YTD 2019 net loss USD 25.6 million. · Equity ratio 59.3% as of 30 September 2019. Oslo, 29 November 2019 Q3 and nine-month 2019 results: MPC Container Ships ASA ("MPCC" or the "Company", together with its subsidiaries the "Group") today published its unaudited financial report for the nine-month period ended 30 September 2019. The Group reports a net loss of USD 11.4

Sivers IMA signs supply agreement with Blu Wireless

Sivers IMA (Nasdaq First North: SIVE) today announced that it has signed an agreement with partner Blu Wireless Technology Ltd (Blu Wireless) for the delivery of radio modules for unlicensed mmWave 5G wireless communication markets such as FWA (Fixed Wireless Access) and track-to-train. First deployments of Blu Wireless’ track-to-train solution are planned during the first quarter of 2020.Sivers IMA (Nasdaq First North: SIVE) today announced that it has signed an agreement with partner Blu Wireless Technology Ltd (Blu Wireless) for the delivery of radio modules for unlicensed mmWave 5G

Imfinzi granted FDA Priority Review for SCLC

29 November 2019 07:00 GMT   Imfinzi granted FDA Priority Review for the treatmentof patients with extensive-stage small cell lung cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).SCLC is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly despite initial response to platinum-based chemotherapy.[1]

Skanska builds new hospital pavilion in Arlington, USA, for USD 37 M, about SEK 350 M

Skanska has signed a contract with Virginia Hospital Center to build a new outpatient pavilion and parking garage in Arlington, Virginia, USA. The contract is worth USD 37 M, about SEK 350 M, which will be included in the US order bookings for the fourth quarter of 2019.The new six-story outpatient pavilion, with a total area of about 21,000 square meters, will house physical therapy examination and treatment rooms, radiology and imaging suites, clinics for examinations and six operating rooms. The parking garage includes three levels below grade and six levels above grade sized to hold 1,

Double Bond Pharmaceutical is seeking a patent for the use of iron succinate

Double Bond Pharmaceutical has filed a Swedish patent application to protect the use of iron succinate for certain indications. Earlier this year, a clinical study, a collaboration between Double Bond Pharmaceutical AB and Skellefteå University, showed that Inofer (iron succinate) significantly improves iron uptake, iron saturation and iron stores in patients with heart failure and iron deficiency. DBP’s subsidiary Drugsson AB, has the distribution right for Inofer (iron succinate) in Sweden, Norway, Denmark and Finland. "We are very pleased that the Inofer study, according to the

Hunter Group ASA - Third Quarter Results 2019

Oslo, 29 November 2019 Financial highlights Net profit from continuing operations came in at USD -1,586t in Q3 2019 compared to USD 632t in Q3 2018. The reduction was mainly due to costs related to the cancelled bank financing and exchange rate fluctuations. Total operating expenses of USD 311t in Q3 2019 were in line with USD 319k in Q3 2018. Key events in Q3 2019 The Company successfully took delivery of Hunter Atla, ahead of the original delivery schedule, hence increasing earnings capacity in Q4 by close to 40 days. The yard completed steel cutting for H.No. 5466 and H.

EQT sells remaining stake in LBX Pharmacy

· EQT Greater China sells remaining 24.78 percent in LBX Pharmacy, a leading discount pharmacy superstore chain in China, at RMB 55.0 per share, 235.2 percent above the IPO price of RMB 16.4 · LBX Pharmacy has experienced strong growth and transformation during EQT’s ownership, leveraging the EQT Network and healthcare sector expertise · LBX Pharmacy’s successful IPO on the Shanghai Stock Exchange in 2015 was the first IPO in China with a foreign private equity fund as control or co-control shareholder The EQT Greater China II fund (“EQT Greater China” or “EQT”) today announced

Castellum invests in Helsingborg – starting construction on GreenHaus and setting up coworking possibilities

Castellum is just beginning construction on the GreenHaus office building with just over 10,000 sq.m. in Oceanhamnen, Helsingborg’s new city district. The total investment for the project, including land acquisition, is calculated to MSEK 300. “It feels very positive that we can start construction on GreenHaus. This is an important project for us in an exciting new city district which has just begun to take form. The building will be WELL-certified and we’re also planning for a major coworking venture,” says Henrik Saxborn, CEO of Castellum AB.  In connection with the GreenHaus

First day of trading in K-Fastigheter class B shares on Nasdaq Stockholm

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONGKONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.K-Fast Holding AB (publ) (“K-Fastigheter” or the “Company”) today announces the outcome of the offer to the general public of the Company’s class B shares (the “Offering”) and the listing of the Company’s

Veidekke ASA: To build offices in Helsingborg for Castellum

Veidekke has been contracted by Castellum to build an office building in Oceanhamnen, Helsingborg. The GreenHaus project is a design and build contract worth SEK 225 million with start-up in December 2019. GreenHaus is part of the urban renewal project H +, with residential units, offices, restaurants and shops on Helsingborg’s waterfront.The office building will comprise a continuous building mass with six floors facing the strait and eight floors facing the harbour basin. The total area encompasses approx. 8,400 m2 above ground and approx. 1,600 m2 of basement area. The premises offer

Induct - Private Placement towards CEO

Induct has completed a Private Placement of NOK 2 million through the subscription of 500,000 new shares at a subscription price of NOK 4.00 per share, through conversion of debt to shares. The shares were subscribed by NPP Capital AS, a company 100% owned by Alf Martin Johansen, who is CEO in Induct AS. The new shares to be issued under the Private Placement will be listed on Merkur Market as soon as practically possible after registration of the share capital increase in the Norwegian Register of Business Enterprises, expected on or about 12 December 2019. NPP Capital AS’s total

Lucara Provides Operating Outlook for 2020

VANCOUVER, November 28, 2019 /CNW/ - (LUC - TSX, LUC - BSE, LUC - Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) is pleased to provide operating guidance for 2020 (all amounts in US Dollars unless otherwise stated). 2020 HIGHLIGHTS • Revenue is forecast to be between $180 million and $210 million;• A capital expenditure of up to $53 million has been approved for early works related to a proposed underground mine at the Karowe Diamond Mine. An investment decision, subject to receipt of all required authorizations and the arrangement of financing,

EAB GROUP PLC: ACQUISITION OF OWN SHARES 28.11.2019

EAB GROUP PLC NOTIFICATION 28.11.2019 at 18:30 EAB GROUP PLC: ACQUISITION OF OWN SHARES 28.11.2019   Date 28.11.2019  Exchange transaction Buy  Share class EAB  Amount 400  Average price/share 2.6200 EURHighest price/share 2.6200 EURLowest price/share 2.6200 EURTotal price 1,048.00 EUR      The shares held by EAB Group Plc on 28.11.2019:   EAB 5,383     On behalf of EAB Group Plc  Skandinaviska Enskilda Banken AB

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2019

Fiskars Corporation  NOTIFICATION 28.11.2019 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 28.11.2019 Date 28.11.2019Exchange transaction BuyShare class FSKRSAmount       1,000Average price/share 11.9550 EUR  Highest price/share 11.9800 EUR Lowest price/share 11.9200 EUR Total price  11,955.00 EUR  The shares held by Fiskars Corporation on 28.11.2019: FSKRS 390,677  On behalf of Fiskars Corporation Skandinaviska Enskilda Banken AB (Publ) Antti Salakka   Mikko

Report of transactions in TORM plc securities by directors, managerial staff and related persons

TORM plc has been notified of the following transaction in TORM plc securities: Name: Jacob MeldgaardReason: Executive DirectorSecurities code (ISIN code): GB00BZ3CNK81Description: SharesTransaction: Exercise of Restricted Share UnitsExercise date: 25 November 2019Market: Outside market, newly issued sharesAmount: 255,345 A sharesExercise price in DKK: 13,712,026.50 CONTACT TORM plcChristopher Everard,

Capital increase in TORM due to exercise of Restricted Share Units as part of the Company’s incentive program

TORM plc (“TORM”) will increase its share capital by 326,233 A-shares (corresponding to a nominal value of USD 3,262.33) as a result of the exercise of a corresponding number of Restricted Share Units. The increase includes the issuance of 255,345 A-shares to TORM plc’s Executive Director, Jacob Meldgaard. The capital increase will be carried out without any pre-emption rights for existing shareholders or others. The new shares have been subscribed for in cash at DKK 53.7 per A-share with a nominal value of USD 0.01 each. The new shares are ordinary shares without any special rights

There are no items matching the current filter
There are no more items matching the current filter
Back to top